Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9050379 | 0.99 | MAOB (0.55) | MAOBBCHEACHE | |
| SCHEMBL6284754 | 0.92 | MAOB (0.45) | MAOBBCHEACHECES1CDC25A | |
| SCHEMBL6284752 | 0.84 | CES1 (0.40) | MAOBBCHEACHECES1CDC25A | |
| SCHEMBL4500323 | 0.84 | MAOB (0.51) | MAOBBCHEACHE | |
| SCHEMBL9047059 | 0.83 | MAOB (0.50) | MAOBBCHEACHE | |
| SCHEMBL9054162 | 0.83 | MAOB (0.57) | MAOBBCHEACHECES1CDC25A | |
| SCHEMBL9062737 | 0.82 | MAOB (0.64) | MAOBBCHEACHECES1CDC25A | |
| SCHEMBL9053947 | 0.81 | MAOB (0.76) | MAOBBCHEACHECES1CDC25A | |
| SCHEMBL9053218 | 0.81 | MAOB (0.63) | MAOBBCHEACHE | |
| SCHEMBL9051412 | 0.80 | PARK7 (0.63) | MAOBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906090-B1 | Compositions and methods for treating mycobacterial diseases | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | claimed |
| EP-1058548-B1 | THE USE OF ISATIN AND OXINDOLE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF MYCOBACTERIAL DISEASE | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | claimed |
| EP-1058548-A1 | NEW USE | AstraZeneca AB (SE) | 2000-12-13 | — | — | EP | claimed |
| WO-1999044608-A1 | NEW USE | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | claimed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6906090-B1 | Compositions and methods for treating mycobacterial diseases | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| EP-1058548-B1 | THE USE OF ISATIN AND OXINDOLE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR USE IN THE TREATMENT OF MYCOBACTERIAL DISEASE | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-1058548-A1 | NEW USE | AstraZeneca AB (SE) | 2000-12-13 | — | — | EP | disclosed |
| WO-1999044608-A1 | NEW USE | ASTRAZENECA AB (SE) | 1999-09-10 | — | — | WO | disclosed |
| EP-0703901-A1 | 1-SUBSTITUTED ISATIN AND OXINDOLE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | Astra Aktiebolag (SE) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994029272-A1 | 1-SUBSTITUTED ISATIN AND OXINDOLE DERIVATIVES AS INHIBITORS OF ACETYLCHOLINESTERASE | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | MAOB 53/4885BCHE 2/4885ACHE 1/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | MAOB 207/4885BCHE 2/4885ACHE 1/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | MAOB 259/4885BCHE 3/4885ACHE 1/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | MAOB 233/4885BCHE 2/4885ACHE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.